With the discovery of new IL-18 variants and the large collection of results of randomized controlled trials, we anticipate the discovery of more non-coding biomarkers for novel diagnostic or therapeutic strategies for T2DM (Zou et al., 2015; Lu et al., 2016; Liu et al., 2017; Wei et al., 2017a,b; Cheng et al., 2018c; Zeng et al., 2018). The gene discussed is IL18; the disease is type 2 diabetes mellitus.